Document Detail


Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects.
MedLine Citation:
PMID:  20090429     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Angiotensin-converting enzyme (ACE) inhibitors are being widely used as antihypertensives by clinicians worldwide. One in every three Americans has hypertension. Hypertension, diabetes, obesity, active smoking, hypercholesterolemia, and inactivity are the major cardiovascular risk factors, which can produce compounding effects on human health, leading to cardiovascular morbidity and mortality. We review the mechanism of action of ACE inhibitors and explain the rationale for using ACE inhibitors not only in hypertensive patients but also in patients with congestive heart failure, acute myocardial infarction, or coronary artery disease. ACE inhibitors can reduce preload and afterload on the heart, prevent ventricular remodeling, and even retard atherogenic changes in the vessel walls. ACE inhibitors can also be helpful in slowing the progression of kidney disease, especially in diabetics. Some studies such as the Heart Outcomes Prevention Evaluation study have shown that ACE inhibitors can reduce the risk of cardiovascular morbidity and mortality, particularly in high-risk individuals. The renin-angiotensin-aldosterone system plays an important role in regulating blood pressure and body volume in the human body. ACE inhibitors and angiotensin-receptor blockers are the two classes of antihypertensives that primarily act on the renin-angiotensin-aldosterone system. We discuss randomized, controlled trials that evaluated different ACE inhibitors and compare them with angiotensin-receptor blockers.
Authors:
Srikanth Katragadda; Rohit R Arora
Related Documents :
19379059 - Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascu...
7484889 - Disparate effects of antihypertensive drugs on large artery distensibility and complian...
6266379 - Vasoactive peptides and hypertension: role of angiotensin converting enzyme.
15824469 - Effects of bradykinin on cardiovascular remodeling in renovascular hypertensive rats.
3555589 - Captopril in combination with hydrochlorothiazide: comparative efficacy vs perceived be...
3038419 - Role of endogenous angiotensin ii and prostaglandins in the antihypertensive mechanism ...
15931959 - Long-term atmospheric mercury wet deposition at underhill, vermont.
8064099 - Postprandial hypotension in 499 elderly persons in a long-term health care facility.
19361899 - A rotating inlay decreases contact pressure on inlay post after posterior cruciate subs...
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  American journal of therapeutics     Volume:  17     ISSN:  1536-3686     ISO Abbreviation:  Am J Ther     Publication Date:    2010 Jan-Feb
Date Detail:
Created Date:  2010-01-21     Completed Date:  2010-03-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9441347     Medline TA:  Am J Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e11-23     Citation Subset:  IM    
Affiliation:
Department of Medicine, Chicago Medical School, North Chicago, IL, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II Type 1 Receptor Blockers / pharmacology,  therapeutic use
Angiotensin-Converting Enzyme Inhibitors / pharmacology*,  therapeutic use
Antihypertensive Agents / pharmacology,  therapeutic use
Heart Diseases / drug therapy*,  physiopathology
Humans
Hypertension / drug therapy*,  epidemiology,  physiopathology
Randomized Controlled Trials as Topic
Renin-Angiotensin System / drug effects
Risk Factors
United States / epidemiology
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Challenges and recommendations for placebo controls in randomized trials in physical and rehabilitat...
Next Document:  Combination therapy in hypertension: a focus on Angiotensin receptor blockers and calcium channel bl...